Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual “Faces of Glaucoma” Campaign and Fundraising Challenge
Bausch + Lomb (NYSE/TSX: BLCO) and Glaucoma Research Foundation (GRF) are launching their second annual 'Faces of Glaucoma' campaign during Glaucoma Awareness Month in January. The initiative aims to raise awareness about glaucoma, the second leading cause of blindness worldwide, by sharing diverse patient stories and educational resources.
The campaign highlights that approximately half of people with glaucoma are unaware they have the condition. As part of the initiative, Bausch + Lomb will match donations up to $20,000 for the fourth consecutive year to support GRF's research toward finding a cure.
The campaign emphasizes that while glaucoma is often associated with older individuals, it can affect anyone regardless of race, age, or gender. Early intervention, including prescription eye drops, can help slow the disease's progression, though there is currently no cure. Detection requires yearly comprehensive dilated eye exams by eye care professionals.
Bausch + Lomb (NYSE/TSX: BLCO) e la Glaucoma Research Foundation (GRF) stanno lanciando la loro seconda campagna annuale 'Faces of Glaucoma' durante il Mese della Consapevolezza sul Glaucoma in gennaio. L'iniziativa ha lo scopo di aumentare la consapevolezza riguardo al glaucoma, la seconda causa principale di cecità nel mondo, condividendo storie di pazienti diverse e risorse educative.
La campagna sottolinea che circa la metà delle persone affette da glaucoma non è consapevole di avere questa condizione. Come parte dell'iniziativa, Bausch + Lomb raddoppierà le donazioni fino a $20.000 per il quarto anno consecutivo per supportare la ricerca della GRF volta a trovare una cura.
La campagna enfatizza che, mentre il glaucoma è spesso associato a persone anziane, può colpire chiunque, indipendentemente da razza, età o genere. Un intervento precoce, inclusi colliri prescritti, può aiutare a rallentare la progressione della malattia, anche se attualmente non esiste una cura. La rilevazione richiede esami oculari dilatati completi annuali effettuati da professionisti della cura degli occhi.
Bausch + Lomb (NYSE/TSX: BLCO) y la Glaucoma Research Foundation (GRF) están lanzando su segunda campaña anual 'Faces of Glaucoma' durante el Mes de Concienciación sobre el Glaucoma en enero. La iniciativa tiene como objetivo aumentar la conciencia sobre el glaucoma, la segunda causa principal de ceguera en el mundo, compartiendo historias diversas de pacientes y recursos educativos.
La campaña destaca que aproximadamente la mitad de las personas con glaucoma no son conscientes de que tienen esta condición. Como parte de la iniciativa, Bausch + Lomb igualará las donaciones hasta $20,000 por cuarto año consecutivo para apoyar la investigación de la GRF en busca de una cura.
La campaña enfatiza que, aunque el glaucoma a menudo se asocia con personas mayores, puede afectar a cualquiera, independientemente de su raza, edad o género. La intervención temprana, incluyendo gotas para los ojos prescritas, puede ayudar a ralentizar la progresión de la enfermedad, aunque actualmente no hay cura. La detección requiere exámenes oculares dilatados comprensivos anuales realizados por profesionales de la salud visual.
바우슈 + 롬 (NYSE/TSX: BLCO)과 녹내장 연구 재단 (GRF)은 1월 녹내장 인식의 달을 맞아 두 번째 연례 캠페인 'Faces of Glaucoma'를 시작합니다. 이 이니셔티브는 다양한 환자 이야기를 공유하고 교육 자료를 통해, 전 세계에서 두 번째로 주요한 실명의 원인인 녹내장에 대한 인식을 높이는 것을 목표로 합니다.
캠페인은 녹내장 환자의 약 절반이 자신이 이 질환을 앓고 있다는 사실을 모르고 있다는 점을 강조합니다. 이 이니셔티브의 일환으로, 바우슈 + 롬은 연구 재단의 연구를 지원하기 위해 4년 연속으로 $20,000까지 기부금을 매칭합니다.
캠페인은 녹내장이 종종 노인과 연관되어 있지만, 인종, 나이, 성별에 관계없이 누구에게나 영향을 미칠 수 있다는 점을 강조합니다. 처방 안구 방울을 포함한 조기 개입은 질병의 진행을 늦추는 데 도움을 줄 수 있으나 현재까지 치료법은 없습니다. 발견을 위해서는 시각 관리 전문가에 의한 연간 종합 확장 안과 검사가 필요합니다.
Bausch + Lomb (NYSE/TSX: BLCO) et la Glaucoma Research Foundation (GRF) lancent leur deuxième campagne annuelle 'Faces of Glaucoma' pendant le mois de sensibilisation au glaucome en janvier. L'initiative vise à sensibiliser le public au glaucome, la deuxième cause principale de cécité dans le monde, en partageant des histoires de patients diverses et des ressources éducatives.
La campagne souligne qu'environ la moitié des personnes atteintes de glaucome ne savent pas qu'elles en souffrent. Dans le cadre de l'initiative, Bausch + Lomb doublc les dons jusqu'à $20,000 pour la quatrième année consécutive afin de soutenir les recherches de la GRF visant à trouver un remède.
La campagne met en avant que, bien que le glaucome soit souvent associé aux personnes âgées, il peut affecter n'importe qui, quel que soit leur race, âge ou sexe. Une intervention précoce, y compris des gouttes ophtalmiques prescrites, peut aider à ralentir la progression de la maladie, bien qu'il n'existe actuellement pas de remède. Le dépistage nécessite des examens oculaires dilatés annuels complets réalisés par des professionnels de la santé oculaire.
Bausch + Lomb (NYSE/TSX: BLCO) und die Glaucoma Research Foundation (GRF) starten ihre zweite jährliche Kampagne 'Faces of Glaucoma' während des Monats zur Aufklärung über Glaukom im Januar. Das Ziel der Initiative ist es, das Bewusstsein für Glaukom zu fördern, die weltweit die zweithäufigste Ursache für Erblindung ist, indem diverse Patientengeschichten und Bildungsressourcen geteilt werden.
Die Kampagne hebt hervor, dass etwa die Hälfte der Personen mit Glaukom sich nicht bewusst ist, dass sie diese Erkrankung haben. Im Rahmen der Initiative wird Bausch + Lomb Spenden bis zu $20.000 im vierten Jahr in Folge verdoppeln, um die Forschung der GRF zur Findung eines Heilmittels zu unterstützen.
Die Kampagne betont, dass Glaukom häufig mit älteren Menschen in Verbindung gebracht wird, aber jeden unabhängig von Rasse, Alter oder Geschlecht betreffen kann. Eine frühzeitige Intervention, einschließlich verschreibungspflichtiger Augentropfen, kann helfen, den Fortschritt der Krankheit zu verlangsamen, obwohl es derzeit keine Heilung gibt. Die Erkennung erfordert jährliche umfassende erweiterte Augenuntersuchungen durch Fachkräfte der Augenheilkunde.
- Partnership with GRF includes matching donations up to $20,000 for research funding
- Continuation of successful awareness campaign demonstrates sustained market presence in eye health sector
- None.
“It’s estimated that half of people with glaucoma don’t know that they have it, demonstrating a need for continuing education and awareness efforts,” said Andrew Stewart, president, Global Pharmaceuticals and International Consumer, Bausch + Lomb. “In collaboration with Glaucoma Research Foundation, we aim to encourage people to take an active role in understanding and managing their risk, starting with seeing an eye doctor.”
Throughout January, Bausch + Lomb and GRF will spotlight educational resources and share stories of individuals and families living with glaucoma to raise awareness of the disease and encourage proactive eye health management. In addition, for the fourth consecutive year, Bausch + Lomb will support a fundraising challenge in which every dollar raised will be matched up to
Glaucoma symptoms can develop gradually and may go unnoticed. Although there is currently no cure for glaucoma, early intervention – including prescription eye drops – can help slow the disease's progression. Only an eye care professional can diagnose glaucoma, typically through a yearly comprehensive dilated eye exam.1,2
“While glaucoma is often thought of as an older person’s disease, it’s important to understand that it can impact anyone, regardless of race, age or gender. This year we build on our previous efforts by highlighting a new group of diverse patient stories to bring to life the many faces of glaucoma,” said Thomas M.
To learn more about the fundraising challenge and listen to patient stories, visit https://glaucoma.org/faces-of-glaucoma/.
About Glaucoma
Glaucoma is a chronic, progressive disease that occurs when excessive eye pressure or other causes lead to damage of the optic nerve. The optic nerve is responsible for the communication of information between the eye and brain. Damage to the optic nerve can lead to severe vision loss, and in the worst case, blindness. As one of the leading causes of preventable blindness, glaucoma affects about four million people in
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in
About Glaucoma Research Foundation
Founded in
References
-
U.S. Centers for Disease Control and Prevention. About Glaucoma. Retrieved from https://www.cdc.gov/vision-health/about-eye-disorders/glaucoma.html. Reviewed on Nov. 12, 2024. - National Eye Institute. Glaucoma and Eye Pressure. Retrieved from https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/glaucoma/glaucoma-and-eye-pressure. Reviewed on Nov. 12, 2024.
- John Hopkins. Glaucoma. Retrieved from https://www.hopkinsmedicine.org/health/conditions-and-diseases/glaucoma. Reviewed on Nov. 12, 2024.
- Ehrlich JR, Burke-Conte Z, Wittenborn JS, et al. Prevalence of Glaucoma Among US Adults in 2022. JAMA Ophthalmol. 2024;142(11):1046–1053. doi:10.1001/jamaophthalmol.2024.3884
© 2024 Bausch + Lomb.
BLNP.0231.USA.24
View source version on businesswire.com: https://www.businesswire.com/news/home/20250107193963/en/
Bausch + Lomb Media Contact:
Caryn Marshall
caryn.marshall@bausch.com
(908) 493-1381
Glaucoma Research Foundation Media Contact:
Andrew J. Jackson
ajackson@glaucoma.org
(415) 986-3162
Source: Bausch + Lomb Corporation
FAQ
What is the 'Faces of Glaucoma' campaign by Bausch + Lomb (BLCO) in 2025?
How much will Bausch + Lomb (BLCO) match in donations for the 2025 glaucoma campaign?
What percentage of people with glaucoma are unaware they have the condition according to BLCO's campaign?
How is Bausch + Lomb (BLCO) contributing to glaucoma research in 2025?
